Proactive Investors interview with CEO
In brief · summary, not quotable
CEO interview published on Proactive Investors discussing FDA support for Phase 2b trial.
Full announcement
Select text to share a quote on X · sign in to keep highlights & notes in your SVNS notes
Solvonis Therapeutics (LON: SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, announces an interview on Proactive Investors with Anthony Tennyson, CEO of the Company. The interview with Anthony Tennyson can be viewed now at https://www.proactiveinvestors.co.uk/companies/news/1064736/solvonis-therapeutics-says-fda-supports-phase-2b-for-awkn-002-candidate-1064736.html.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.